Second-Quarter 2023 Results: Net Sales of $945.0 Million, Representing Year-Over-Year Growth of 11% Excluding Inflammation Medicines GAAP Net Income of $127.1 Million; Adjusted EBITDA of.
First-Quarter 2023 Results: Net Sales of $832.1 Million GAAP Net Income of $54.7 Million; Adjusted EBITDA of $232.9 Million TEPEZZA® Net Sales of $405.3 Million . | May 3, 2023